Device Trial Radar · NCT06934096
Ultrasound of the Spleen Utilizing Low-energy (Diagnostic Level) Insonification.
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
39
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Jun 7, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Northwell HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GE Healthcare
- First posted
- Apr 18, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a three-cohort, randomized, double-blinded , sham-controlled, single-center, early feasibility research trial to determine whether organ-specific biologic effects on platelet activity and coagulation are achievable through selective ultrasound of the spleen utilizing low-energy (diagnostic-level) insonification. * Group 1: Focused insonification at center of the spleen. * Group 2: Prolonged duration insonification at center of the spleen * Group 3: Prolonged duration insonification across the spleen. Participants will receive 30 minutes of sham stimulation in the randomized group that is assigned to them, followed by active stimulation within the same group. Blood biomarkers (local and systemic) will be measured before and at several timepoints after stimulation to measure the molecular and cellular effects of the device
Conditions
- Hemostasis
- Blood Biomarkers
- Ultrasound
Interventions
Ultrasound Pulsed Doppler Imaging SystemDevice
Ultrasound pulsed doppler system accompanied with the abdominal curvilinear probe will be used for the purpose of collecting the data for the endpoints.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine whether diagnostic-level ultrasound to the spleen can modulate systemic blood biomarkers of hemostasisTime frame: 4 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Feinstein Institute for Medical Research
Manhasset, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.